Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy

Pranav Sharma, Kamran Zargar-Shoshtari, Philippe E. Spiess, Wade J. Sexton, Michael A. Poch
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA

INTRODUCTION

Radical cystoprostatectomy (RC) with bilateral pelvic lymph node dissection is currently the preferred treatment for high-risk bladder cancer (BC) such as muscle-invasive bladder cancer (MIBC), persistent carcinoma in situ (CIS), or refractory high-grade non-MIBC. The prevalence of prostatic disease at the time of RC, however, is highly variable and often difficult to predict. Routine prostatic sampling to more accurately determine clinical stage prior to RC is controversial but important to consider, especially in patients that are candidates for orthotopic diversion. Prior prostatic radiation therapy (XRT), however, may affect the prevalence of prostatic malignancy at the time of RC. Rates of residual prostatic disease in this setting are relatively unknown, and whether routine sampling

Abstract

Purpose: We determined the prevalence of prostatic malignancy in patients undergoing radical cystoprostatectomy (RC) for urothelial carcinoma (UC) with a history of radiation therapy (XRT) treatment for prostatic adenocarcinoma (PCa).

Materials and Methods: Fifty-three men who underwent a RC for UC that were previously treated for PCa with XRT were retrospectively identified. Pathology reports were reviewed to assess for residual PCa or prostatic UC at the time of surgery.

Results: Thirteen (25%) patients had residual PCa, 16 (30%) had prostatic UC, and 8 (15%) had both. Sixteen (30%) patients had no evidence of prostatic disease. Patients with PCa had median tumor volume of 2.2 cc (interquartile range: 1.2–2.5 cc) and one-third had high-risk features (Gleason score >8 or pT3-T4 disease). Sixteen of 24 patients (67%) with prostatic UC had a stromal invasion, 5 (21%) had a ductal invasion, and 3 (13%) had carcinoma in situ. Tumors at bladder neck or trigone during transurethral resection were predictive of prostatic UC (odds ratio: 4.32, 95% confidence interval: 1.2–15.5, \( P = 0.025 \)).

Conclusions: Despite prior XRT for PCa, less than one-third of patients had no prostatic disease at the time of RC. Routine prostatic sampling should be considered in these patients especially if considering the orthotopic diversion.

Key Words: Pathology, prostate cancer, radiation, radical cystectomy, urothelial carcinoma

Address for correspondence:
Dr. Pranav Sharma, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. E-mail: pranav.sharma@moffitt.org
Received: 20.04.2015, Accepted: 30.06.2015

How to cite this article: Sharma P, Zargar-Shoshtari K, Spiess PE, Sexton WJ, Poch MA. Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. Urol Ann 2016;8:151-6.
of the prostate is necessary for appropriate clinical staging in this patient population is a topic of discussion.

The purpose of this study was to determine the degree of prostatic malignancy in the RC specimens of urothelial carcinoma (UC) patients who were previously treated with XRT for prostatic adenocarcinoma (PCa). By assessing the amount of tumor in these patients, we hoped to determine if routine preoperative sampling of the prostate is necessary for adequate staging prior to RC. Traditional risk factors associated with prostatic UC were also analyzed to determine if any were predictors of prostatic extension in this patient population.

**MATERIALS AND METHODS**

**Data source**

After Institutional Review Board approval, we retrospectively analyzed the charts of 767 patients treated with RC for high-risk BC at our institution from 2003 to 2013. We identified 64 patients who had undergone pelvic XRT for PCa prior to their BC diagnosis with an appropriate treatment response. Patients with non-UC histology, a prior prostatectomy, and known prostatic UC were excluded, leaving 53 patients in our study population with clinical T1, or T2 UC. No patient had clinical evidence of prostatic disease on either digital rectal examination (DRE) or cystoscopy. We noted the method of pelvic XRT used as well as any prior use of androgen deprivation therapy (ADT). Due to the time interval between diagnoses and the fact that most patients received treatment at an outside facility, pre-XRT Gleason scores and post-XRT prostate specific antigen (PSA) levels were not available.

**Assessment of prostate pathology**

Pathology reports from the RC specimens were used to determine which patients had no prostatic malignancy versus those that harbored adenocarcinoma or UC at the time of RC. For patients with PCa, we recorded the Gleason score, margin status, pathological tumor (pT) stage and calculated the tumor volume. Tumor volume measurements were accomplished by estimating the volume of the entire prostate using the standard ellipsoid formula: Width × height × length × π/6 (dimensions were obtained from the pathologist’s measurement of the specimen). This volume was then multiplied by the percentage of the prostate that was involved with adenocarcinoma (based on the pathologist’s assessment). For patients with prostatic UC, we noted the depth of invasion (CIS vs. ductal invasion vs. stromal invasion) and any associated seminal vesicle (SV) extension. Noncontiguous prostatic stromal involvement arising from within the urethra (i.e. subepithelial stromal invasion) was also distinguished from tumor extending transmurally through the bladder wall and into the stroma of the prostate (pT4a).

**Study variables**

The demographic and clinical characteristics were recorded for our study population, including age, body mass index (in kg/m²), preoperative creatinine (Cr [in mg/dl]), smoking history, American Society of Anesthesiologists (ASA) Physical Status classification score, use of neoadjuvant chemotherapy, clinical tumor (cT) stage, presence of CIS or multifocal tumors on transurethral resection (TUR), and bladder tumor location at the time of TUR. Preoperative Cr levels were drawn 2–4 weeks prior to RC, and ASA score was determined by the anesthesiologist on the morning of surgery. For bladder tumor location, we differentiated bladder neck (BN) or trigonal involvement from all other areas in the bladder (dome, lateral, anterior, posterior wall) due to the theoretical higher risk of prostatic invasion. The presence of CIS, multifocal tumors, bladder tumor location, and cT stage were based on operative reports and pathology from any TUR (at our institution or at an outside hospital) that occurred before RC. The most aggressive pathology was recorded, and any patient with a history of BN or trigonal involvement (even in cases with multifocal tumors) was grouped into this category.

**Statistical analysis**

Clinicodemographic variables were compared between patients with and without prostatic UC. Continuous variables were reported as medians and interquartile ranges (IQRs), and categorical variables were reported as frequency counts and percentages. We used the Mann–Whitney U-test to determine any differences in medians between the two groups and the Fisher’s exact test for proportions. Logistic regression was performed to evaluate the association of these variables with prostatic UC. All factors that were found to be strong predictors on univariable analysis (P < 0.2) were included on the final multivariable model.

Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) Software Package version 21.0 (IBM Corporation, Armonk, NY, USA). All tests were two-sided with a P < 0.05 considered as statistically significant.

**RESULTS**

**Demographic and clinical characteristics**

Median age of our study cohort was 76.8 years (IQR: 74.3–81.0) [Table 1]. The median time between PCa and UC diagnosis was 6 years (IQR: 3–10.3) although the date of PCa treatment was not known in five patients. The majority of patients (49%) were previously treated with brachytherapy for their PCa while 32% received external-beam XRT, and 19% had both.
The majority of patients (83%) underwent RC for MIBC, and 19% received chemotherapy prior to surgery. Sixty-two percent of patients had bladder tumors at the BN or trigone diagnosed on TUR, and 23% had CIS.

**Prostate pathology**

On review of the prostatic portion of RC specimens, 25% of patients had residual adenocarcinoma, 30% had UC, and 15% had both [Table 2]. Less than one-third of patients (30%) had no evidence of tumor within the prostate at the time of surgery.

Median tumor volume for those patients with PCa was 2.2 cc (IQR: 1.2–2.5 cc), and only 10% had a tumor volume <0.5 cc. Twenty-nine percent of patients with PCa had a Gleason score >8, and 33% had pT3-T4 disease. The positive margin rate associated with PCa was 29%.

Of those patients with prostatic UC, 67% had a stromal invasion, 21% had a ductal invasion, and 13% had CIS. Direct extension of tumor into the prostate (pT4a) was responsible for most cases of stromal invasion (88%) while 13% arose from within the urethra. Fifty-seven percent of patients with pT4a UC had additional SV involvement as well.

**Prostatic urothelial carcinoma**

Patients with and without prostatic extension of UC had similar demographic and clinical features [Table 3]. There was also no difference between the two groups in either the method of XRT or the usage of ADT in the treatment of their PCa. Patients with prostatic UC, however, were more likely to have tumors at the BN or trigone on TUR (P = 0.026).

On univariable analysis, preoperative Cr and BN/trigonal involvement on TUR were found to be strongly associated with prostatic UC [Table 4]. On multivariable analysis, however, only BN/trigonal involvement on TUR was found to be an independent predictor of prostatic UC (odds ratio: 4.32, 95% confidence interval: 1.2–15.5, P = 0.025).

**DISCUSSION**

This study, to our knowledge, represents the first report looking at the prevalence and features of undiagnosed PCa or prostatic UC in RC patients previously treated with pelvic XRT. Although this represents a unique subgroup of the RC population, the findings are still relevant given the increasing number of older men that are treated for PCa with XRT every year.[2]

The prevalence of prostatic malignancy in RC patients without prior pelvic XRT is well documented. Revelo et al. reported a 41% prevalence of PCa and a 48% prevalence of prostatic UC in 121 consecutive RC specimens.[3] Forty-four percent of patients with PCa had a tumor volume >0.5 cc, 16% had >pT3 disease, and 4% had a Gleason score >8. The positive

---

**Table 1: Demographic and clinical characteristics**

| Characteristic                  | Total, n=53 |
|--------------------------------|-------------|
| Median age, years (IQR)         | 76.8 (74.3-81.0) |
| Median BMI, kg/m² (IQR)         | 28.1 (25.1-31.5) |
| Smoking history, n (%)          |             |
| Never                           | 5 (9)       |
| Former                          | 43 (81)     |
| Current                         | 5 (9)       |
| Prior XRT for PCa, n (%)        |             |
| Brachytherapy                   | 26 (49)     |
| EBRT                            | 17 (32)     |
| Brachytherapy + EBRT            | 10 (19)     |
| Prior ADT for PCa, n (%)        | 14 (26)     |
| ASA score, n (%)                |             |
| 2                               | 14 (26)     |
| 3                               | 39 (74)     |
| Median preoperative creatinine, mg/dl (IQR) | 1.3 (1.0-1.6) |
| Neoadjuvant chemotherapy, n (%) | 10 (19)     |
| Bladder tumor location on TUR, n (%) |         |
| BN/trigone                      | 33 (62)     |
| Other                           | 20 (38)     |
| Multifocal tumors, n (%)        | 20 (38)     |
| cT stage, n (%)                 |             |
| cTis                            | 3 (6)       |
| cTa-T1                          | 6 (11)      |
| cT2                             | 44 (83)     |
| Concurrent CIS, n (%)           | 12 (23)     |

**ASA**: American Society of Anesthesiologists, **BMI**: Body mass index, **BN**: Bladder neck, **CIS**: Carcinoma in situ, **EBRT**: External-beam radiation therapy, **XRT**: Radiation therapy, **PCa**: Prostate adenocarcinoma, **UC**: Urothelial carcinoma, **TUR**: Transurethral resection, **cT**: Clinical tumor

**Table 2: Pathological characteristics of prostate specimens**

| Characteristic                  | Total, n=53 |
|--------------------------------|-------------|
| Prostate pathology, n (%)      |             |
| Adenocarcinoma                 | 13 (25)     |
| UC                             | 16 (30)     |
| Adenocarcinoma + UC            | 8 (15)      |
| None                           | 16 (30)     |
| Prostatic adenocarcinoma       | Total, n=21 |
| Tumor volume, n (%)            |             |
| <0.5 cc                        | 2 (10)      |
| 0.5-5 cc                       | 16 (76)     |
| >5 cc                          | 3 (14)      |
| Gleason score, n (%)           |             |
| 6                              | 9 (43)      |
| 7                              | 6 (29)      |
| >8                             | 6 (29)      |
| pT stage, n (%)                |             |
| pT2                            | 14 (67)     |
| pT3-T4                         | 7 (33)      |
| Prostate UC, n (%)             |             |
| CIS                            | 3 (13)      |
| Ductal invasion                | 5 (21)      |
| Stromal invasion               | 16 (67)     |
| Direct extension (pT4a)        | 14 (58)     |
| Intraurethral (noncontiguous)  | 2 (8)       |
| SV involvement                 | 8 (33)      |

**ADT**: Androgen deprivation therapy, **CIS**: Carcinoma in situ, **EBRT**: External-beam radiation therapy, **PCa**: Prostate adenocarcinoma, **pT**: Pathologic tumor, **RC**: Radical cystoprostatectomy, **SV**: Seminal vesicle, **UC**: Urothelial carcinoma, **XRT**: Radiation therapy
Table 3: Patients with versus without prostatic UC

|                      | No prostatic UC, n=29 | Prostatic UC, n=24 | P    |
|----------------------|------------------------|--------------------|------|
| Median age, years (IQR) | 76.7 (74.6-81.0) | 78.0 (72.1-81.3) | 0.67 |
| Median BMI, kg/m² (IQR) | 28.5 (25.1-31.8) | 27.8 (25.3-30.8) | 0.51 |
| Prior XRT for PCa, n (%) | 16 (55) | 10 (42) | 0.41 |
| Smoking (current or former), n (%) | 26 (90) | 22 (92) | >0.99 |
| ASA score, n (%) | | | |
| 1-2 | 9 (31) | 5 (21) | 0.54 |
| >3 | 20 (69) | 19 (79) | 0.25 |
| Median pre-op creatinine, mg/dL (IQR) | 1.2 (1-1.5) | 1.4 (1.1-1.8) | 0.026 |
| Neoadjuvant chemotherapy, n (%) | 6 (21) | 4 (17) | >0.99 |
| Primary tumor location, n (%) | | | |
| BN/trigone | 14 (48) | 19 (79) | 0.40 |
| Other | 15 (52) | 5 (21) | 0.40 |
| Multifocal tumors, n (%) | 11 (38) | 9 (38) | >0.99 |
| cT stage, n (%) | | | |
| <cT1 | 6 (21) | 3 (13) | 0.49 |
| cT2-T4 | 23 (79) | 21 (87) | 0.49 |
| Concurrent CIS, n (%) | 8 (28) | 4 (17) | 0.51 |

ADT: Androgen deprivation therapy, ASA: American Society of Anesthesiologists, BMI: Body mass index, BN: Bladder neck, CIS: Carcinoma in situ, EBRT: External beam radiation therapy, IQR: Interquartile range, PCa: Prostatic adenocarcinoma, UC: Urothelial carcinoma, XRT: Radiation therapy, cT: Clinical tumor

Table 4: Predictors of prostatic UC

|                      | OR | 95% CI Lower | 95% CI Upper | P    |
|----------------------|----|--------------|--------------|------|
| Univariate           |    |              |              |      |
| Age                  | 0.97 | 0.90 | 1.05 | 0.48 |
| BMI                  | 0.94 | 0.83 | 1.07 | 0.35 |
| Preoperative Cr      | 2.16 | 0.75 | 6.19 | 0.15 |
| +Smoking Hx          | 1.27 | 0.19 | 8.29 | 0.80 |
| ASA >3               | 1.71 | 0.49 | 6.03 | 0.40 |
| +Neoadjuvant chemo   | 0.77 | 0.19 | 3.11 | 0.71 |
| +BN/trigone          | 4.07 | 1.20 | 13.86 | 0.025 |
| +Multifocal          | 0.98 | 0.32 | 3.30 | 0.97 |
| cT2-T4               | 1.83 | 0.41 | 8.24 | 0.43 |
| +CIS                 | 0.53 | 0.14 | 2.02 | 0.35 |
| +EBRT PCa            | 1.72 | 0.58 | 5.14 | 0.33 |
| +ADT PCa             | 0.59 | 0.17 | 2.06 | 0.40 |
| Multivariate         |    |              |              |      |
| Preoperative Cr      | 2.30 | 0.78 | 8.60 | 0.13 |
| +BN/trigone          | 4.32 | 1.20 | 15.53 | 0.025 |

ADT: Androgen deprivation therapy, ASA: American Society of Anesthesiologists, BMI: Body mass index, BN: Bladder neck, CI: Confidence interval, CIS: Carcinoma in situ, Cr: Creatinine, cT: Clinical tumor, EBRT: External beam radiation therapy, Hx: History, OR: Odds ratio, PCa: Prostatic adenocarcinoma, UC: Urothelial carcinoma

Interestingly, our study population had a similar prevalence of prostatic malignancy at the time of RC compared to prior studies in nonirradiated patients. The severity of the prostatic disease, however, was significantly worse. PCa was seen in 40% of patients in our study, and prostatic UC was seen in 45%. Approximately, one-third of patients with PCa, however, had high-risk features with Gleason score >8 or pT3-T4 disease. Median tumor volume was 2.2 cc, and this increased in conjunction with Gleason score and tumor stage. Patients with a Gleason score of 6–7 had an average tumor volume of 1.54 cc, but those with Gleason >8 disease had an average tumor volume of 5.9 cc. Similarly, patients with prostatic UC had an aggressive disease with 67% having a stromal invasion, 58% having pT4a disease, and 33% having SV involvement.

It is unclear why this cohort of RC patients with prior pelvic XRT had the more severe prostatic disease compared to nonirradiated RC patients reported on in the prior literature. One theory proposed is that pelvic XRT may have a deleterious effect on normal prostatic and urothelial tissues, promoting the development of more aggressive tumors in the future. Further large-scale, prospective studies, however, are necessary to validate any theory regarding the behavior of secondary malignancies in the setting of prior XRT. The majority of patients in our study were also treated with brachytherapy alone for their PCa, which has shown worse long-term oncological outcomes for the intermediate and high-risk disease. In addition, since patients were treated for their PCa at a median of 6 years prior to their UC diagnosis, the dosage and treatment patterns of XRT could reflect older, less effective regimens used at that time.

Prior studies have looked at risk factors for prostatic involvement of UC in patients undergoing RC with prior pelvic XRT. Nixon et al. showed that CIS and tumor multifocality were independent predictors of prostatic UC. Patel et al. similarly showed that bladder CIS and trigonal involvement of bladder tumors were independent risk factors for prostatic
Finally, Mazzucchelli et al. showed that multifocal tumors, tumors at the BN or trigone, and history of multiple tumor recurrences were all associated with an increased risk of prostatic UC.[10] In this study, we found that bladder tumors at the BN or trigone were again strongly associated with prostatic UC in patients with prior pelvic XRT, supporting the use of routine prostatic sampling in this setting.

Routine prostatic sampling of all patients with high-risk UC of the bladder continues to be a source of debate with regards to appropriate clinical staging prior to RC. Currently, neither the National Comprehensive Cancer Network or the European Association of Urology make definitive recommendations regarding prostatic urethral biopsies in these patients as part of the clinical work-up, especially in patients considering the orthotopic urinary diversion.[11] There is data to suggest that frozen section of the apical prostatic urethral margin at the time of RC is superior to preoperative TUR biopsy in determining the prevalence of prostate UC.[12,13] A recent study by von Rundstedt et al. of 272 patients with UC who underwent RC, however, showed a 100% positive predictive value and 86% negative predictive value of TUR biopsy to detect prostatic UC when taken adjacent to the verumontanum.[14] The overall rate of prostatic UC was 37.1% in this study, but TUR biopsy missed most prostatic tumors resulting from the transmural invasion of the bladder primary lesion (4 of 15 patients).

There are several limitations to this study. In addition to the smaller sample size and retrospective nature of the analysis, we were unable to obtain pretreatment PSA levels, Gleason scores, or staging information in our study cohort. PSA levels prior to RC were also inconsistently drawn and not readily available. Dosages and duration of XRT were largely unknown because the majority of patients had their PCa treated at outside institutions. As such, we were unable to correlate the severity of prostatic disease with PSA levels before surgery, and we were unable to measure reliably predictors of PCa recurrence in our study population.

While earlier guidelines did not endorse Gleason scoring on post-XRT prostate pathology due to tumor dedifferentiation, a trend toward higher Gleason scores, and histological changes resulting from treatment effect, the topic still remains controversial.[15,16] Recent multi-institutional studies have included pathologic Gleason scores on salvage prostatectomy specimens post-XRT as predictors of biochemical recurrence, metastasis, and cancer-specific death.[17,18] As such, we included post-XRT Gleason scores and tumor stage as a frame of reference for tumor severity.

Gleason scoring can also be affected by the usage of prior hormonal therapy, which occurred in 26% of our study group. Prior ADT has been reported to lead to higher Gleason scores, decreased tumor volume, less capsular penetration, and lower surgical margin involvement.[19,21] While Gleason scores for PCa may have been overestimated in a small subset of patients in this study, pathologic stage, margin status, and tumor volume may have been underestimated.

CONCLUSION

Undiagnosed prostatic disease in RC patients with a prior history of pelvic XRT for PCa can be equally as prevalent and even more aggressive than in RC patients without prior prostatic XRT. Cognizant use of PSA, DRE, and preoperative prostatic biopsy is necessary to appropriate stage these patients with high-risk BC and provide the most appropriate surgical treatment, especially in patients considering the orthotopic diversion.

Financial support and sponsorship Nil.

Conflicts of interest There are no conflicts of interest.

REFERENCES

1. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol 2014;65:778-92.
2. Hoffman KE. Management of older men with clinically localized prostate cancer: The significance of advanced age and comorbidity. Semin Radiat Oncol 2012;22:284-94.
3. Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr, Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostate cancers from cystoprostatectomies: Implications for possible apical sparing surgery. J Urol 2008;179:S27-32.
4. Barbisan F, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Kirkali Z, et al. Urothelial and incidental prostatic carcinoma in prostates from cystoprostatectomies for bladder cancer: Is there a relationship between urothelial and prostate cancer? BJU Int 2009;103:1058-63.
5. Bruins HM, Djaladat H, Ahmadi H, Sherrod A, Cai J, Miranda G, et al. Incidental prostate cancer in patients with bladder urothelial carcinoma: Comprehensive analysis of 1,476 radical cystoprostatectomy specimens. J Urol 2013;190:1704-9.
6. Rosenberg JE, Chen MH, Nguyen PL, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer. Clin Genitourin Cancer 2012;10:21-5.
7. Wattson DA, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, et al. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: Implications for treatment selection. Int J Radiat Oncol Biol Phys 2012;82:e773-9.
8. Nixon RG, Chang SS, Lafleur BJ, Smith JJ, Cookson MS. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 2002;167:502-5.
9. Patel SG, Cookson MS, Barcos DA, Clark PE, Smith JA Jr, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int 2009;104:933-7.
10. Mazzucchelli R, Barbisan F, Santinelli A, Scarpelli M, Galosi AB, Lopez-Beltran A, et al. Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. Urology 2009;74:385-90.

11. Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, et al. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw 2006;4:984-1014.

12. Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, et al. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol 2008;180:164-7.

13. Lebret T, Hervé JM, Barré P, Gaudez F, Lugagne PM, Barbagelatta M, et al. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatectomy. Eur Urol 1998;33:170-4.

14. von Rundstedt FC, Lerner SP, Godoy G, Amiel G, Wheeler TM, Truong LD, et al. Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. J Urol 2015;193:58-63.

15. Bostwick DG, Foster CS. Predictive factors in prostate cancer: Current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17:222-72.

16. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355-67.

17. Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: A systematic review of the literature. Eur Urol 2012;61:961-71.

18. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: A multi-institutional collaboration. Eur Urol 2011;60:205-10.

19. Bentley G, Dey J, Sakr WA, Wood DP Jr, Pontes JE, Grignon DJ. Significance of the Gleason scoring system after neoadjuvant hormonal therapy. Mol Urol 2000;4:125.

20. Roznovanu SL, Radulescu D, Novac C, Stolnicu S. The morphologic changes induced by hormone and radiation therapy on prostate carcinoma. Rev Med Chir Soc Med Nat Iasi 2005;109:337-42.

21. Têtu B. Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma. Best Pract Res Clin Endocrinol Metab 2008;22:271-83.